ProCE Banner Activity

HIMALAYA: Patient-Reported Outcomes for Patients With Unresectable Hepatocellular Carcinoma Receiving Durvalumab ± Tremelimumab

Slideset Download
Conference Coverage
Compared with sorafenib treatment alone, addition of a single dose of tremelimumab to durvalumab in STRIDE and durvalumab monotherapy were associated with meaningful, patient-centered benefits for patients with unresectable hepatocellular carcinoma.

Released: June 06, 2022

Expiration: June 05, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab